ANDY GRACEY MANAGER OF AUSTRALIAN ETHICAL EMERGING COMPANIES FUND tips stocks for 2016
we like the science behind oncolytic virus drug developer Viralytics (VLA) which are trialling a cancer immunotherapy therapy, used in combination with future block buster selling drugs called check point inhibitors; Yervoy and Keytruda. Immunotherapies have the potential to drastically change the cancer treatment landscape by using the human bodies own defence systems. We believe if the company is able to demonstrate incremental benefits when combined with checkpoint inhibitors, Viralytics will definitely be acquired in 2016 or 2017 for big dollars.
VLA Price at posting:
69.0¢ Sentiment: Hold Disclosure: Held
